(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of 94.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.3%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Abivax Sa's revenue in 2025 is $10,089,010.On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $638,956,901, with the lowest ABVX revenue forecast at $314,034,762, and the highest ABVX revenue forecast at $947,768,239. On average, 3 Wall Street analysts forecast ABVX's revenue for 2026 to be $633,292,948, with the lowest ABVX revenue forecast at $314,034,762, and the highest ABVX revenue forecast at $947,768,239.
In 2027, ABVX is forecast to generate $5,847,402,784 in revenue, with the lowest revenue forecast at $4,171,816,505 and the highest revenue forecast at $7,522,989,064.